Pharmaceuticals News and Research

RSS

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.

12 May 2015

Leicester research team identifies potential new targets for cancer treatments

An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments...

12 May 2015

Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

In a major advance in the field of neuropsychiatry, researchers in the Vollum Institute at Oregon Health & Science University have illuminated how cocaine and amphetamines disrupt the normal functioning of the dopamine transporter in the brain.

12 May 2015

Study highlights potential new targets for development of novel cancer therapy

12 May 2015

JHL Biotech closes $45.6 million Series C round of financing

JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds managed by a global renowned crossover fund with over US$1.6 trillion in AUM, with participation from existing investor Milestone Capital and new investors Sungent BioVenture and Liwick Investment Management.

12 May 2015

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.

11 May 2015

Boehringer Ingelheim, Sutter Health announce health care innovation collaboration

Boehringer Ingelheim, a family-owned biopharmaceutical company, and Sutter Health, a not-for-profit health system in Northern California, today announced the start of a five-year research and health care innovation collaboration, which will explore and test the value of digital health solutions, mobile technologies, and insights from advanced data analytics in the delivery of health care.

11 May 2015

MJFF announces acquisition of parkin research tools from Imago Pharmaceuticals

The Michael J. Fox Foundation for Parkinson's Research announces the acquisition of a library of research tools around the parkin protein from Imago Pharmaceuticals. The Foundation believes these tools — cell lines, plasmids, compounds and more — will accelerate biological study and drug development against this promising disease-modification target.

11 May 2015

The future of cancer treatment set to be transformed through the opening of new Cancer Institute

NHS patients will soon benefit from the opening of a new cancer centre specialising in the use of diagnostics for targeted cancer medicines used to treat some of the UK’s most common cancers...

11 May 2015

UNC-Chapel Hill, GSK partner to find cure for HIV/AIDS

The University of North Carolina at Chapel Hill, a leading global public research university with significant expertise in HIV basic and clinical research, and GSK, a global, research-based pharmaceutical and healthcare company with a legacy of success in developing treatments for HIV, today announced the creation of the dedicated HIV Cure center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS.

11 May 2015

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others. The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.

8 May 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.

8 May 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

The World Health Organization (WHO) today published the new edition of its Model List of Essential Medicines) which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others...

8 May 2015

Anton Paar polarimeters: New LED light source and air pump for sample cells maximize lifetime and ease of use.

Anton Paar now launches a new LED light source. A new integrated air pump makes cleaning and drying sample cells a lot more convenient...

From Anton Paar GmbH 8 May 2015

Cyclenium Pharma, Haplogen sign agreement to discover novel pharmaceutical candidates

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on its proprietary macrocyclic chemistry technology, and Haplogen GmbH, a biotechnology company developing anti-infective drugs, today announced the signing of a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas.

7 May 2015

Unique real-time drug monitoring system

Titan Enterprises assisted CRISI in the early days of development of the unique flow sensor used in the BD Intelliport™, a medication management system for manual intravenous (IV) bolus injections...

From Titan Enterprises Ltd 7 May 2015

Egalet announces business highlights, financial results for first quarter 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today reported business highlights and financial results for the three months ended March 31, 2015.

7 May 2015

BD reports revenues of $2.051 billion for second fiscal quarter 2015

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for the second fiscal quarter ended March 31, 2015, representing a decrease of 1.0 percent from the prior-year period, or an increase of 4.9 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 7 May 2015

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Phosphate Therapeutics Limited, a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD).

7 May 2015

Pharmaceuticals News and Research

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Leicester research team identifies potential new targets for cancer treatments

Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

Study highlights potential new targets for development of novel cancer therapy

JHL Biotech closes $45.6 million Series C round of financing

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Boehringer Ingelheim, Sutter Health announce health care innovation collaboration

MJFF announces acquisition of parkin research tools from Imago Pharmaceuticals

The future of cancer treatment set to be transformed through the opening of new Cancer Institute

UNC-Chapel Hill, GSK partner to find cure for HIV/AIDS

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

Orexigen Therapeutics provides update on business and financial results for Q1 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

Anton Paar polarimeters: New LED light source and air pump for sample cells maximize lifetime and ease of use.

Cyclenium Pharma, Haplogen sign agreement to discover novel pharmaceutical candidates

Unique real-time drug monitoring system

Egalet announces business highlights, financial results for first quarter 2015

BD reports revenues of $2.051 billion for second fiscal quarter 2015

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring